SCCL
MCID: SML038
MIFTS: 67

Small Cell Cancer of the Lung (SCCL)

Categories: Cancer diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Small Cell Cancer of the Lung

MalaCards integrated aliases for Small Cell Cancer of the Lung:

Name: Small Cell Cancer of the Lung 57
Small Cell Lung Cancer 75 53 59 37 29 55 6
Lung Small Cell Carcinoma 12 53 15
Small-Cell Cancer of Lung 57 13
Small Cell Lung Carcinoma 44 17
Sclc 57 59
Small Cell Neuroendocrine Carcinoma of the Lung 53
Small Cell Carcinoma of Lung 72
Cancer, Lung, Small Cell 40
Carcinoma, Small Cell 72
Oat Cell Lung Cancer 53
Sclc; Sccl 57
Sclc1 57
Sccl 57

Characteristics:

Orphanet epidemiological data:

59
small cell lung cancer
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Adult;

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
small cell cancer of the lung:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 59  
Rare respiratory diseases


External Ids:

Disease Ontology 12 DOID:5409
OMIM 57 182280
KEGG 37 H00013
MeSH 44 D055752
NCIt 50 C4917
ICD10 via Orphanet 34 C34.9
UMLS via Orphanet 73 C0149925
Orphanet 59 ORPHA70573
MedGen 42 C0149925
UMLS 72 C0149925 C0262584

Summaries for Small Cell Cancer of the Lung

KEGG : 37
Lung cancer is a leading cause of cancer death among men and women in industrialized countries. Small cell lung carcinoma (SCLC) is a highly aggressive neoplasm, which accounts for approximately 25% of all lung cancer cases. Molecular mechanisms altered in SCLC include induced expression of oncogene, MYC, and loss of tumorsuppressor genes, such as p53, PTEN, RB, and FHIT. The overexpression of MYC proteins in SCLC is largely a result of gene amplification. Such overexpression leads to more rapid proliferation and loss of terminal differentiation. Mutation or deletion of p53 or PTEN can lead to more rapid proliferation and reduced apoptosis. The retinoblastoma gene RB1 encodes a nuclear phosphoprotein that helps to regulate cell-cycle progression. The fragile histidine triad gene FHIT encodes the enzyme diadenosine triphosphate hydrolase, which is thought to have an indirect role in proapoptosis and cell-cycle control.

MalaCards based summary : Small Cell Cancer of the Lung, also known as small cell lung cancer, is related to small cell carcinoma of the bladder and lung squamous cell carcinoma. An important gene associated with Small Cell Cancer of the Lung is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are Small cell lung cancer and MicroRNAs in cancer. The drugs Vinblastine and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and lymph node, and related phenotype is neoplasm of the lung.

Disease Ontology : 12 A lung carcinoma that has material basis in primitive-appearing cells that are smaller than normal cells and is located in the lung.

Wikipedia : 75 Small-cell carcinoma is a type of highly malignant cancer that most commonly arises within the lung,... more...

More information from OMIM: 182280

Related Diseases for Small Cell Cancer of the Lung

Diseases in the Lung Large Cell Carcinoma family:

Small Cell Cancer of the Lung Lung Clear Cell Carcinoma

Diseases related to Small Cell Cancer of the Lung via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1159)
# Related Disease Score Top Affiliating Genes
1 small cell carcinoma of the bladder 33.5 SYP ENO2 CHGA
2 lung squamous cell carcinoma 32.5 TUG1 TP53 PTEN PIK3CA CCAT2
3 lung benign neoplasm 32.2 TP53 SYP ENO2 CHGA
4 glioblastoma multiforme 31.9 TP53 RB1 PTEN PIK3CA MIR21
5 lung cancer 31.9 TUG1 TP73 TP53 TOP1 SYP RB1
6 pituitary tumors 31.8 SST RB1 POMC
7 bronchial adenomas/carcinoids childhood 31.6 SST POMC
8 kidney cancer 31.6 TP53 MIR21 MALAT1 HOTAIR
9 bladder cancer 31.6 TUG1 TP53 RB1 MIR21 MALAT1 HOTAIR
10 osteogenic sarcoma 31.6 TUG1 TP53 RB1 MALAT1 HOTTIP HOTAIR
11 myeloma, multiple 31.5 TUG1 TP53 MALAT1 HOTAIR
12 leukemia, acute myeloid 31.5 TUG1 TP53 MIR21 MALAT1 HOTAIR
13 glioblastoma 31.5 TUG1 TP53 RB1 PTEN PIK3CA MIR21
14 carcinosarcoma 31.5 TP53 PTEN PIK3CA
15 squamous cell carcinoma, head and neck 31.4 TP53 RB1 PTEN PIK3CA MIR21 HOTAIR
16 pancreatic ductal adenocarcinoma 31.4 MIR21 MALAT1 HOTTIP HOTAIR
17 pituitary adenoma 31.4 MALAT1 HOTAIR CCAT2
18 pulmonary large cell neuroendocrine carcinoma 31.4 SYP ENO2 CHGA
19 esophageal cancer 31.4 TP53 RB1 PTEN PIK3CA MIR21 MALAT1
20 intrahepatic cholangiocarcinoma 31.4 TUG1 TP53 CCAT2
21 carcinoid tumors, intestinal 31.4 SYP SST ENO2 CHGA
22 pancreatic cancer 31.4 TUG1 TP53 SST PIK3CA MIR21 MALAT1
23 small cell carcinoma 31.4 TP53 SYP PTEN ENO2 CHGA CALCA
24 teratoma 31.3 TP53 SYP ENO2
25 ovarian cancer 31.3 TUG1 TP53 TOP1 PTEN PIK3CA MIR21
26 ectopic cushing syndrome 31.3 SYP SST POMC
27 large cell neuroendocrine carcinoma 31.3 SYP ENO2 CHGA
28 lung cancer susceptibility 3 31.3 TUG1 TP53 PIK3CA MALAT1 HOTAIR
29 lung oat cell carcinoma 31.3 POMC ENO2 CHGA CALCA
30 hydrocephalus 31.2 TP53 SYP PTEN ENO2
31 retinoblastoma 31.2 TP53 RB1 MALAT1 HOTAIR
32 suppression of tumorigenicity 12 31.2 TP53 PTEN PIK3CA GRPR CHGA
33 oral squamous cell carcinoma 31.2 TUG1 MIR21 MALAT1 HOTAIR CCAT2
34 colorectal cancer 31.2 TUG1 TP53 TOP1 PTEN PIK3CA MIR21
35 breast adenocarcinoma 31.2 TP53 PTEN PIK3CA CALCA
36 ovarian epithelial cancer 31.2 PIK3CA MALAT1 HOTAIR
37 gastric adenocarcinoma 31.2 TP53 PTEN PIK3CA HOTAIR CHGA
38 hemangioma 31.1 SYP PTEN ENO2 CHGA
39 nervous system cancer 31.1 TP53 SYP RB1 PTEN ENO2
40 bronchus adenoma 31.1 SST POMC
41 rhabdoid cancer 31.1 TP53 SYP ENO2
42 paraganglioma 31.1 SYP SST ENO2 CHGA
43 cholangiocarcinoma 31.1 TUG1 TP53 PTEN PIK3CA MIR21 MALAT1
44 large cell carcinoma 31.1 SYP ENO2 CHGA
45 pulmonary blastoma 31.1 TP53 SYP CHGA
46 basaloid squamous cell carcinoma 31.1 TP53 SYP ENO2
47 adenocarcinoma 31.1 TP53 RB1 PTEN PIK3CA MALAT1
48 brain cancer 31.1 TP73 TP53 TOP1 SYP RB1 PTEN
49 malignant glioma 31.0 TUG1 HOTTIP HOTAIR
50 olfactory neuroblastoma 31.0 SYP ENO2 CHGA

Graphical network of the top 20 diseases related to Small Cell Cancer of the Lung:



Diseases related to Small Cell Cancer of the Lung

Symptoms & Phenotypes for Small Cell Cancer of the Lung

Human phenotypes related to Small Cell Cancer of the Lung:

32
# Description HPO Frequency HPO Source Accession
1 neoplasm of the lung 32 HP:0100526

Symptoms via clinical synopsis from OMIM:

57
Oncology:
small-cell lung cancer

Lab:
3p23-p14 chromosome deletion in tumor

Misc:
sensitive to chemotherapy and radiotherapy

Clinical features from OMIM:

182280

Drugs & Therapeutics for Small Cell Cancer of the Lung

DrugBank drugs 16 :

(show all 8)
# Drug Name Indication DrugBank ID
1 Atezolizumab Atezolizumab is indicated to treat locally or advanced metastatic urothelial carcinoma in patients ineligible for cicplatin-containing chemotherapy with tumors expressing PD-L1, in patients ineligible for cisplatin-containing chemotherapy irrespective of PD-L1, have disease progression following platinum containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant chemotherapy.[L7489] Atezolizumab is also indicated first line for non small cell lung cancer in combination with bevacizumab, paclitaxel, and carboplatin with no EGFR or ALK genomic abnormalities.[L7489] It can be used in patients with disease progression during or after platinum containing chemotherapy even if they have EGFR and ALK abnormalities.[L7489] Atezolizumab is indicated in combination with paclitaxel protein-bound to treat locally advanced or metastatic triple negative breast cancer expressing PD-L1.[L7489] Finally, atezolizumab is indicated in combination with carboplatin and etoposide as first line treatment for extensive stage small cell lung cancer.[L7489] DB11595
2 Cisplatin For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer. DB00515
3 Docetaxel For the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer. DB01248
4 Etoposide For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme. DB00773
5 Ifosfamide Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma. DB01181
6 Irinotecan For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. DB00762
7 Methotrexate Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis.[L7144] Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.[L7147,L7150] Other formulations are indicated to treat gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-Hodgkin's lymphoma.[L7180] It is also used in the maintenance of acute lymphocytic leukemia.[L7180] Methotrexate is also given before treatment with leucovorin to prolong relapse-free survival following surgical removal of a tumour in non-metastatic osteosarcoma.[L7180] DB00563
8 Vincristine Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). DB00541

Drugs for Small Cell Cancer of the Lung (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 782)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vinblastine Approved Phase 4 865-21-4 241903 13342
2
Nicotine Approved Phase 4 54-11-5 942 89594
3
Caffeine Approved Phase 4 58-08-2 2519
4
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
5
tannic acid Approved Phase 4 1401-55-4
6
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
7
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
8
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
9
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
11
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
12
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
13
Remifentanil Approved Phase 4 132875-61-7 60815
14
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
15
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
16
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
17
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
18
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
19
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
20
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
21
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
22
Imidacloprid Vet_approved Phase 4 105827-78-9 86418
23 Flurbiprofen axetil Investigational Phase 4 91503-79-6
24 Cholinergic Agents Phase 4
25 Nicotinic Agonists Phase 4
26 N-Methylaspartate Phase 4
27 alanine Phase 4
28
Bilirubin Phase 4 635-65-4, 69853-43-6 5280352 21252250
29 acivicin Phase 4
30 Analgesics Phase 4
31 Analgesics, Non-Narcotic Phase 4
32 Anesthetics, Local Phase 4
33 Anesthetics Phase 4
34 Hypnotics and Sedatives Phase 4
35 Anesthetics, Inhalation Phase 4
36 Platelet Aggregation Inhibitors Phase 4
37
Apatinib Phase 4 811803-05-1
38 Hormone Antagonists Phase 4
39 Hormones Phase 4
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
41 Tranquilizing Agents Phase 4
42 Central Nervous System Depressants Phase 4
43 Gastrointestinal Agents Phase 4
44 Antiemetics Phase 4
45 HIV Protease Inhibitors Phase 4
46
protease inhibitors Phase 4
47 glucocorticoids Phase 4
48 Antineoplastic Agents, Hormonal Phase 4
49 Autonomic Agents Phase 4
50 BB 1101 Phase 4

Interventional clinical trials:

(show top 50) (show all 5415)
# Name Status NCT ID Phase Drugs
1 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer: a Multi-center, Randomized, Open Label Study Unknown status NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
2 Pharmacokinetics of Carboplatin After Adjusted Dosing for High BMI, Low Serum Creatinine, and Maximal Renal Function Unknown status NCT02103244 Phase 4 Carboplatin
3 High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE): a Randomized, Open-label Study Unknown status NCT02404675 Phase 4 icotinib
4 The Exploratory Clinical Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin (Endostar) for Local Advanced Non-small Cell Lung Cancer (NSCLC (Ⅲ A / Ⅲ B) ) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
5 A Study of Endostar in Combination With Chemotherapy Followed by Endostar Maintenance Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4 Endostar;Gemcitabine-Cisplatin chemotherapy
6 A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4 Yangzhengxiaoji Capsule;Placebo Capsule
7 Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Unknown status NCT02513355 Phase 4 Changchun marina;cisplatin;Taxol;parapl
8 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
9 A Single Center, Open Label, Multicenter Study to Determine the Safety and Efficacy of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases Unknown status NCT01926171 Phase 4 Icotinib plus WBRT
10 Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
11 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
12 An Open Lable, Single Arm, Phase IV Study of Icotinib as First-line Treatment in Elder NSCLC Patients With EGFR Mutation Unknown status NCT01646450 Phase 4 Icotinib
13 A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia Unknown status NCT02553187 Phase 4 Kanglaite Injection
14 Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin Unknown status NCT01336192 Phase 4 Gemcitabine;Best supportive care
15 Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy
16 Recombinant Human Endostatin Durative Transfusion Combined With Pemetrexed Plus Cisplatin or Carboplatin in the First-line Treatment of Advanced Lung Adenocarcinoma With Wild-type EGFR or ALK-negative Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
17 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
18 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
19 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
20 A Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Completed NCT01287754 Phase 4 erlotinib [Tarceva]
21 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4 erlotinib [Tarceva]
22 A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA®) as a Second-line Therapy in NSCLC Patients Completed NCT00608868 Phase 4 Gefitinib
23 A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis Completed NCT00099541 Phase 4 zoledronic acid
24 A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan Completed NCT01196078 Phase 4 erlotinib [Tarceva];vinorelbine
25 Post-marketing Clinical Trial of Induction Chemotherapy of Pemetrexed Plus Carboplatin Followed by Pemetrexed Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer Completed NCT01020786 Phase 4 Pemetrexed;Carboplatin
26 A Multi-centre, Open-label, Phase IV, Interventional Study to Evaluate the Efficacy of Erlotinib (Tarceva®) Following 4 Cycles of Platinum-based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy Completed NCT01230710 Phase 4 Erlotinib
27 A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
28 An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer Completed NCT00949910 Phase 4 Erlotinib
29 A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
30 An Open Label, Single-arm Phase IV Study to Assess the Efficacy and Safety of Afatinib as Second-line Therapy for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harbouring an EGFR Mutation (Del19 or L858R) Who Have Failed First-line Treatment With Platinum-based Chemotherapy Completed NCT02208843 Phase 4 Afatinib
31 An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa Completed NCT01000740 Phase 4
32 Open Label Study of Erlotinib (Tarceva®) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
33 A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (StageIIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who HaveNot Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy Completed NCT00770588 Phase 4 Gefitinib;Placebo
34 Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]
35 Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy Completed NCT00380718 Phase 4 pemetrexed
36 Clinical Study of Recombinant Human Endostatin Combined With NP Chemotherapy in the Treatment of Stage ⅢA Non Small Cell Lung Cancer Completed NCT02497118 Phase 4 Endostatin;Vinorelbine;Cisplatin
37 A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations Completed NCT02514174 Phase 4 Afatinib
38 Ensure Extension Study to Assess the PFS of First-Line Erlotinib (Tarceva®) and Erlotinib After the Time of Disease Progression in Chinese Population Enrolled in the Ensure Trial Completed NCT02000531 Phase 4 Erlotinib;Chemotherapy
39 An Open , Single-Center, Single Arm Trial to Evaluate the Efficacy and Safety of Dose Escalation of Icotinib in Advanced NSCLC Patients After Routine Icotinib Therapy Completed NCT01465243 Phase 4 Icotinib
40 An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First Line Treatment in Caucasian Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed NCT01203917 Phase 4 Gefitinib
41 Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients With Resected Non-small Cell Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
42 Phase IV Randomized Trial of Pemetrexed Followed by Docetaxel or in Reverse Sequence in Non-small-cell Lung Cancer Patients Failed Previous Chemotherapy Completed NCT01442909 Phase 4 Docetaxel and pemetrexed
43 Phase IV Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin in Previously Untreated, Inoperable (Stage IIIa or IIIb) Non-small-cell Lung Cancer Completed NCT00686322 Phase 4 Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
44 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
45 Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer Completed NCT03092986 Phase 4 Paclitaxel;Carboplatin;Cisplatin;Vinblastine Sulfate
46 Randomized Cross-over Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC. A Phase IV Study. Completed NCT01848613 Phase 4 Vinorelbine
47 Phase IV/II Open-label Study to Evaluate Prompt Response to Treatment With Cisplatin, Gemcitabine and Bevacizumab in Patients With Non-small Lung Cancer. Completed NCT02316327 Phase 4 gemcitabine, cisplatin and bevacizumab
48 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
49 A Prospective Multi-center Randomized Study of the Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
50 A Phase 3b/4 Safety Trial of Flat Dose Nivolumab In Combination With Ipilimumab in Participants With Non-Small Cell Lung Cancer Recruiting NCT02869789 Phase 4 Nivolumab in combination with Ipilimumab

Search NIH Clinical Center for Small Cell Cancer of the Lung

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Atezolizumab
Cisplatin
Cisplatin
CISPLATIN PWDR
Docetaxel
Etoposide
Ifosfamide
Irinotecan
Methotrexate
Teniposide
Topotecan
Topotecan Hydrochloride
Vincristine

Cochrane evidence based reviews: small cell lung carcinoma

Genetic Tests for Small Cell Cancer of the Lung

Genetic tests related to Small Cell Cancer of the Lung:

# Genetic test Affiliating Genes
1 Small Cell Lung Cancer 29 RB1

Anatomical Context for Small Cell Cancer of the Lung

MalaCards organs/tissues related to Small Cell Cancer of the Lung:

41
Lung, Brain, Lymph Node, Breast, Testes, T Cells, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Small Cell Cancer of the Lung:

19
Lung

Publications for Small Cell Cancer of the Lung

Articles related to Small Cell Cancer of the Lung:

(show top 50) (show all 30844)
# Title Authors PMID Year
1
Comprehensive genomic profiles of small cell lung cancer. 38 8
26168399 2015
2
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. 38 8
22941189 2012
3
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. 38 8
22941188 2012
4
Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. 38 8
12629553 2003
5
Microsatellite alterations in plasma DNA of small cell lung cancer patients. 38 8
8782463 1996
6
An unusually proximal deletion on the short arm of chromosome 3 in a patient with small cell lung cancer. 38 8
1672284 1991
7
Localization of human ERBA2 to the 3p22----3p24.1 region of chromosome 3 and variable deletion in small cell lung cancer. 38 8
2848257 1988
8
Restriction fragment length polymorphism studies show consistent loss of chromosome 3p alleles in small cell lung cancer patients' tumors. 38 8
2900253 1988
9
Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. 38 8
2821400 1987
10
Loss of heterozygosity for a chromosome 3 sequence presumably at 3p21 in small cell lung cancer. 38 8
2885082 1987
11
Small cell lung cancer cell line derived from a primary tumor with a characteristic deletion of 3p. 38 8
3030544 1987
12
A unique cell-surface protein phenotype distinguishes human small-cell from non-small-cell lung cancer. 38 8
6289311 1982
13
A nonrandom chromosomal abnormality, del 3p(14-23), in human small cell lung cancer (SCLC). 38 8
6286098 1982
14
Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). 38 8
6274023 1982
15
Definition of a tumor suppressor locus within human chromosome 3p21-p22. 8
1438292 1992
16
Three distinct regions involved in 3p deletion in human lung cancer. 8
1347916 1992
17
Oncogenic point mutations in the human retinoblastoma gene: their application to genetic counseling. 71
2594029 1989
18
Loss of heterozygosity in a gene coding for a thyroid hormone receptor in lung cancers. 8
2536219 1989
19
Molecular genetics of lung cancer. 8
3289123 1988
20
Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. 8
2892196 1987
21
Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. 8
2825033 1987
22
Molecular analysis of the short arm of chromosome 3 in small-cell and non-small-cell carcinoma of the lung. 8
2821398 1987
23
Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. 8
2998591 1985
24
A 3p deletion in small cell lung carcinoma. 8
2982478 1985
25
Small cell carcinoma of the lung: macrophage-specific antigens suggest hemopoietic stem cell origin. 8
6089338 1984
26
Human lung small-cell carcinoma contains bombesin. 8
6285381 1982
27
Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. 8
6265067 1981
28
Neuron-specific enolase is produced by neuroendocrine tumours. 8
6111674 1981
29
Cytogenetic effects of cigarette smoke condensates in vitro and in vivo. 8
7333590 1981
30
MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. 88
20508945 2011
31
Non-receptor tyrosine kinase Etk is involved in the apoptosis of small cell lung cancer cells. 9 38
20206622 2010
32
INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. 9 38
20420527 2010
33
Glucocorticoid receptor over-expression promotes human small cell lung cancer apoptosis in vivo and thereby slows tumor growth. 9 38
20015838 2010
34
Non-receptor tyrosine kinase Etk regulation of drug resistance in small-cell lung cancer. 9 38
20004564 2010
35
Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer. 9 38
20078550 2009
36
Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer. 9 38
19889201 2009
37
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. 9 38
19887547 2009
38
Flow cytometric detection of small cell lung cancer cells with aberrant CD45 expression in micrometastatic bone marrow. 9 38
19674995 2009
39
Caveolin-1 is an important factor for the metastasis and proliferation of human small cell lung cancer NCI-H446 cell. 9 38
19718715 2009
40
Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer. 9 38
19679880 2009
41
Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. 9 38
19372561 2009
42
Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: implication of c-Src and its inhibitor. 9 38
19212674 2009
43
Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice. 9 38
19139120 2009
44
Small cell lung cancer: significance of RB alterations and TTF-1 expression in its carcinogenesis, phenotype, and biology. 9 38
19390995 2009
45
Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature. 9 38
19149760 2009
46
Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. 9 38
19047109 2008
47
[Relationship between vascular endothelial growth factor C expression level and lymph node metastasis in non small cell lung cancer]. 9 38
19080076 2008
48
Epidermal growth factor receptor mutations in small cell lung cancer. 9 38
18829487 2008
49
ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. 9 38
19031951 2008
50
A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells. 9 38
18421308 2008

Variations for Small Cell Cancer of the Lung

ClinVar genetic disease variations for Small Cell Cancer of the Lung:

6 (show top 50) (show all 106)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 PTEN NM_000314.7(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic rs121909224 10:89692904-89692904 10:87933147-87933147
2 TP53 NM_000546.5(TP53): c.537T> G (p.His179Gln) single nucleotide variant Pathogenic rs876660821 17:7578393-7578393 17:7675075-7675075
3 TP53 NM_000546.5(TP53): c.818G> T (p.Arg273Leu) single nucleotide variant Pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
4 TP53 NM_000546.5(TP53): c.517G> T (p.Val173Leu) single nucleotide variant Pathogenic rs876660754 17:7578413-7578413 17:7675095-7675095
5 subset of 54 genes:SPAST chr2: 29446394..42552694 inversion inversion Pathogenic 2:29446394-42552694 :0-0
6 PTEN NM_000314.7(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 10:89692905-89692905 10:87933148-87933148
7 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 17:7577539-7577539 17:7674221-7674221
8 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
9 RB1 NM_000321.2(RB1): c.1981C> T (p.Arg661Trp) single nucleotide variant Pathogenic rs137853294 13:49033844-49033844 13:48459708-48459708
10 PIK3CA NM_006218.4(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
11 RB1 NM_000321.2(RB1): c.1215+1G> A single nucleotide variant Pathogenic rs587776783 13:48947629-48947629 13:48373493-48373493
12 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic rs148924904 17:7578442-7578442 17:7675124-7675124
13 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
14 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic rs786201059 17:7577082-7577082 17:7673764-7673764
15 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 17:7577580-7577580 17:7674262-7674262
16 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 17:7578395-7578395 17:7675077-7675077
17 PIK3CA NM_006218.4(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 3:178936082-178936082 3:179218294-179218294
18 PIK3CA NM_006218.4(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 3:178936093-178936093 3:179218305-179218305
19 TP53 NM_000546.5(TP53): c.517G> A (p.Val173Met) single nucleotide variant Pathogenic/Likely pathogenic rs876660754 17:7578413-7578413 17:7675095-7675095
20 TP53 NM_000546.5(TP53): c.818G> C (p.Arg273Pro) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
21 PIK3CA NM_006218.4(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 3:178936091-178936091 3:179218303-179218303
22 PIK3CA NM_006218.4(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
23 RB1 NM_000321.2(RB1): c.2242G> T (p.Glu748Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121913297 13:49039164-49039164 13:48465028-48465028
24 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 17:7577538-7577538 17:7674220-7674220
25 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
26 TP53 NM_000546.5(TP53): c.700T> C (p.Tyr234His) single nucleotide variant Pathogenic/Likely pathogenic rs864622237 17:7577581-7577581 17:7674263-7674263
27 TP53 NM_000546.5(TP53): c.817C> A (p.Arg273Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913343 17:7577121-7577121 17:7673803-7673803
28 PTEN NM_000314.7(PTEN): c.389G> T (p.Arg130Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 10:89692905-89692905 10:87933148-87933148
29 TP53 NM_000546.5(TP53): c.730G> A (p.Gly244Ser) single nucleotide variant Pathogenic/Likely pathogenic rs1057519989 17:7577551-7577551 17:7674233-7674233
30 TP53 NM_000546.5(TP53): c.731G> A (p.Gly244Asp) single nucleotide variant Pathogenic/Likely pathogenic rs985033810 17:7577550-7577550 17:7674232-7674232
31 PIK3CA NM_006218.4(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs104886003 3:178936091-178936091 3:179218303-179218303
32 PIK3CA NM_006218.4(PIK3CA): c.1624G> C (p.Glu542Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 3:178936082-178936082 3:179218294-179218294
33 RB1 NM_000321.2(RB1): c.2117G> T (p.Cys706Phe) single nucleotide variant Likely pathogenic rs121913295 13:49037877-49037877 13:48463741-48463741
34 B2M NM_004048.3(B2M): c.3G> A (p.Met1Ile) single nucleotide variant Likely pathogenic rs1057519877 15:45003747-45003747 15:44711549-44711549
35 B2M NM_004048.3(B2M): c.1A> G (p.Met1Val) single nucleotide variant Likely pathogenic rs1023835002 15:45003745-45003745 15:44711547-44711547
36 B2M NM_004048.3(B2M): c.1A> T (p.Met1Leu) single nucleotide variant Likely pathogenic rs1023835002 15:45003745-45003745 15:44711547-44711547
37 B2M NM_004048.3(B2M): c.2T> C (p.Met1Thr) single nucleotide variant Likely pathogenic rs1057519879 15:45003746-45003746 15:44711548-44711548
38 B2M NM_004048.3(B2M): c.2T> G (p.Met1Arg) single nucleotide variant Likely pathogenic rs1057519879 15:45003746-45003746 15:44711548-44711548
39 PIK3CA NM_006218.4(PIK3CA): c.1625A> C (p.Glu542Ala) single nucleotide variant Likely pathogenic rs1057519927 3:178936083-178936083 3:179218295-179218295
40 PIK3CA NM_006218.4(PIK3CA): c.1625A> T (p.Glu542Val) single nucleotide variant Likely pathogenic rs1057519927 3:178936083-178936083 3:179218295-179218295
41 PIK3CA NM_006218.4(PIK3CA): c.1625A> G (p.Glu542Gly) single nucleotide variant Likely pathogenic rs1057519927 3:178936083-178936083 3:179218295-179218295
42 TP53 NM_000546.5(TP53): c.746G> C (p.Arg249Thr) single nucleotide variant Likely pathogenic rs587782329 17:7577535-7577535 17:7674217-7674217
43 TP53 NM_000546.5(TP53): c.856G> C (p.Glu286Gln) single nucleotide variant Likely pathogenic rs786201059 17:7577082-7577082 17:7673764-7673764
44 TP53 NM_000546.5(TP53): c.857A> T (p.Glu286Val) single nucleotide variant Likely pathogenic rs1057519985 17:7577081-7577081 17:7673763-7673763
45 TP53 NM_000546.5(TP53): c.857A> C (p.Glu286Ala) single nucleotide variant Likely pathogenic rs1057519985 17:7577081-7577081 17:7673763-7673763
46 TP53 NM_000546.5(TP53): c.731G> T (p.Gly244Val) single nucleotide variant Likely pathogenic rs985033810 17:7577550-7577550 17:7674232-7674232
47 TP53 NM_000546.5(TP53): c.730G> C (p.Gly244Arg) single nucleotide variant Likely pathogenic rs1057519989 17:7577551-7577551 17:7674233-7674233
48 TP53 NM_000546.5(TP53): c.535C> G (p.His179Asp) single nucleotide variant Likely pathogenic rs587780070 17:7578395-7578395 17:7675077-7675077
49 TP53 NM_000546.5(TP53): c.536A> C (p.His179Pro) single nucleotide variant Likely pathogenic rs1057519991 17:7578394-7578394 17:7675076-7675076
50 TP53 NM_000546.5(TP53): c.578A> C (p.His193Pro) single nucleotide variant Likely pathogenic rs786201838 17:7578271-7578271 17:7674953-7674953

Copy number variations for Small Cell Cancer of the Lung from CNVD:

7 (show top 50) (show all 515)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 15909 1 120235683 147296355 Substitutions and indels small cell lung cancer
2 18774 1 147306435 159745095 Substitutions and indels small cell lung cancer
3 21590 1 159753915 159864147 Substitutions and indels small cell lung cancer
4 21631 1 159879159 167481135 Substitutions and indels small cell lung cancer
5 22562 1 167488767 167515635 Substitutions and indels small cell lung cancer
6 22575 1 167524383 182844003 Substitutions and indels small cell lung cancer
7 22643 1 16801095 16840107 Substitutions and in dels small cell lung cancer
8 22724 1 16861959 29150031 Substitutions and in dels small cell lung cancer
9 24621 1 182849019 182888703 Substitutions and indels small cell lung cancer
10 24623 1 182893695 194979795 Substitutions and indels small cell lung cancer
11 25853 1 194993223 195074031 Substitutions and indels small cell lung cancer
12 25942 1 195088143 205083387 Substitutions and indels small cell lung cancer
13 27160 1 205088907 205109547 Substitutions and indels small cell lung cancer
14 27163 1 205114395 208124379 Substitutions and indels small cell lung cancer
15 27411 1 208129227 208155879 Substitutions and indels small cell lung cancer
16 27424 1 208162923 222138663 Substitutions and indels small cell lung cancer
17 28412 1 222150063 222281979 Substitutions and indels small cell lung cancer
18 28435 1 222297471 247249719 Substitutions and indels small cell lung cancer
19 31650 1 29155527 30043083 Substitutions and in dels small cell lung cancer
20 31718 1 30048807 41173191 Substitutions and in dels small cell lung cancer
21 32828 1 39746 16783059 Substitutions and in dels small cell lung cancer
22 33011 1 41174800 41175800 Intrachromosomal rea rrangement small cell lung cancer
23 33013 1 41178543 42371163 Substitutions and in dels small cell lung cancer
24 33099 1 42374208 42375208 Intrachromosomal rea rrangement small cell lung cancer
25 33100 1 42376011 42579327 Substitutions and in dels small cell lung cancer
26 33116 1 42583395 42584395 Intrachromosomal rea rrangement small cell lung cancer
27 33117 1 42584427 44255643 Substitutions and in dels small cell lung cancer
28 33294 1 44259752 44260752 Intrachromosomal rea rrangement small cell lung cancer
29 33295 1 44260511 44261511 Intrachromosomal rea rrangement small cell lung cancer
30 33296 1 44260527 44275323 Substitutions and in dels small cell lung cancer
31 33300 1 44279330 44280330 Intrachromosomal rea rrangement small cell lung cancer
32 33301 1 44279742 44280742 Intrachromosomal rea rrangement small cell lung cancer
33 33302 1 44280303 48578211 Substitutions and in dels small cell lung cancer
34 33819 1 48580747 48581747 Intrachromosomal rea rrangement small cell lung cancer
35 33821 1 48583227 51275739 Substitutions and in dels small cell lung cancer
36 33980 1 51279608 51280608 Intrachromosomal rea rrangement small cell lung cancer
37 33981 1 51281079 54467547 Substitutions and in dels small cell lung cancer
38 34296 1 54469360 54470360 Intrachromosomal rea rrangement small cell lung cancer
39 34297 1 54473247 54557103 Substitutions and in dels small cell lung cancer
40 34301 1 54561497 54562497 Intrachromosomal rea rrangement small cell lung cancer
41 34302 1 54562083 54649251 Substitutions and in dels small cell lung cancer
42 34322 1 54652634 54653634 Intrachromosomal rea rrangement small cell lung cancer
43 34323 1 54654159 57627915 Substitutions and in dels small cell lung cancer
44 34908 1 57632775 57657135 Substitutions and in dels small cell lung cancer
45 34910 1 57661947 72536187 Substitutions and in dels small cell lung cancer
46 36221 1 72541191 72583059 Substitutions and in dels small cell lung cancer
47 36257 1 72587919 85749039 Substitutions and in dels small cell lung cancer
48 37122 1 85755495 85774959 Substitutions and in dels small cell lung cancer
49 37129 1 85779879 120230763 Substitutions and in dels small cell lung cancer
50 41421 10 17866791 18173655 Substitutions and in dels small cell lung cancer

Expression for Small Cell Cancer of the Lung

Search GEO for disease gene expression data for Small Cell Cancer of the Lung.

Pathways for Small Cell Cancer of the Lung

Pathways related to Small Cell Cancer of the Lung according to KEGG:

37
# Name Kegg Source Accession
1 Small cell lung cancer hsa05222
2 MicroRNAs in cancer hsa05206

GO Terms for Small Cell Cancer of the Lung

Cellular components related to Small Cell Cancer of the Lung according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 PML body GO:0016605 8.8 TP53 RB1 PTEN

Biological processes related to Small Cell Cancer of the Lung according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.65 TP53 SST RB1 PTEN MIR21
2 neuropeptide signaling pathway GO:0007218 9.37 POMC GRPR
3 regulation of blood pressure GO:0008217 9.33 POMC CHGA CALCA
4 positive regulation of macrophage differentiation GO:0045651 9.32 RB1 CALCA
5 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.13 RB1 PTEN MIR21
6 endothelial cell migration GO:0043542 8.8 PTEN PIK3CA CALCA

Sources for Small Cell Cancer of the Lung

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....